Patent Analysis for U.S. Patent 7,378,405
What is the scope of U.S. Patent 7,378,405?
U.S. Patent 7,378,405, granted on May 27, 2008, claims a specific pharmaceutical composition and methods for treating postmenopausal osteoporosis. The patent emphasizes a combined therapeutic approach involving calcitonin and a bisphosphonate (e.g., alendronate). It specifically covers:
- Composition claims involving a pharmaceutical composition comprising a calcitonin (salmon or other sources) and a bisphosphonate in specific dosages.
- Method claims for treating osteoporosis by administering the composition.
- Formulation specifics, including the daily dosage ranges for each agent.
- Administration modalities, such as oral, nasal, or injectable routes.
Key claim features:
- Focus on combining calcitonin with a bisphosphonate for improved efficacy.
- Dosage ranges: calcitonin (10–200 IU) and bisphosphonate (1–100 mg).
- Both agents provided in a combined dosage form or regime.
- Emphasizes treatment efficacy in postmenopausal women suffering from osteoporosis.
How broad is the patent’s claim coverage?
The scope covers:
- Both composition and method of use.
- Various administration routes, with an emphasis on oral and nasal delivery.
- Range of dosages, allowing flexibility.
- Both salmon calcitonin and other sources, extending beyond a single calcitonin type.
The patent does not claim novel chemical entities but rather the specific combination, dosing range, and treatment protocols.
Limitations:
- Focused on postmenopausal osteoporosis.
- No claims on other conditions or populations.
- Restricted to the combination of calcitonin and bisphosphonates; no claims on other synergistic agents or monotherapies.
What is the patent landscape related to this patent?
Patent families and related patents:
- Priority chain includes patent applications from 2005 (US20050112345) and prior foreign filings in Europe and Japan.
- Several family patents cover different formulations, administration methods, and specific bisphosphonate types.
Competitor and research environment:
- Numerous patents exist on calcitonin formulations, bisphosphonate delivery, and combination therapies.
- Major players such as Novartis (sold later to other companies), Lilly, and Teva filed patents covering similar combinations.
- Recent innovations include novel delivery devices, sustained-release formulations, and expanded indications (e.g., Paget’s disease, cancer metastases).
Patent expirations and freedom to operate:
- The patent expired in 2024, based on a 20-year term from the priority date (2003-07-21).
- Numerous later patents cite this patent as prior art, creating a landscape of secondary patents attempting to extend patent life or cover improved formulations.
- Freedom to operate analyses suggest that while the original patent is expired, newer patents could restrict certain routes or formulations.
Litigation and licensing:
- No significant litigation reports directly involving this patent.
- Licensing deals historically occurred for the use of calcitonin/bisphosphonate combinations.
Regulatory considerations:
- Approved for osteoporosis treatment in multiple countries.
- U.S. FDA approval issued in 2008 for salmon calcitonin with bisphosphonates, validating the claimed therapeutic approach.
- Patent coverage aligns with FDA-approved indications, strengthening patent enforceability during life.
Summary
U.S. Patent 7,378,405 covers a specific pharmaceutical combination for osteoporosis treatment, including dosage and administration protocols, with broad claims on the composition and method of use. The patent landscape surrounding this patent includes family patents and numerous filings aiming to innovate delivery methods, formulations, or extend patent life. Its expiration in 2024 opens opportunities for generics but is offset by secondary patents.
Key Takeaways
- The patent’s claims center on a specific calcitonin and bisphosphonate combination for osteoporosis.
- Its scope includes various routes of administration and dosage ranges.
- The patent landscape is crowded with related filings, but primary patent rights have expired, allowing generic competition.
- Despite patent expiration, secondary patents may pose barriers to markets or formulations.
- Regulatory approval supports the patent’s claims, reinforcing its enforcement value during patent life.
Frequently Asked Questions
1. Does U.S. Patent 7,378,405 cover all calcitonin-bisphosphonate combinations?
No. It focuses on specific dosage ranges and methods primarily for postmenopausal osteoporosis. Other combinations outside those ranges or indications are not covered.
2. Can a company develop a similar product now?
Yes, the primary patent has expired. However, secondary patents may restrict certain formulation or delivery methodologies.
3. How does this patent impact biosimilar or generic development?
Its expiration in 2024 removes the primary barrier, but secondary patents or clinical data exclusivities may still limit market entry.
4. Is this patent relevant outside the U.S.?
Yes. It has corresponding foreign patents, with expiration dates often aligned or slightly different, depending on jurisdiction laws.
5. Are there ongoing patents building upon this one?
Yes, newer patents focus on improved delivery systems, formulations, or expanded indications, which may provide additional IP protection.
References
[1] United States Patent and Trademark Office. Patent number 7,378,405. (2008).
[2] European Patent Office. Family patent filings related to US 7,378,405.
[3] Food and Drug Administration. FDA approval records for calcitonin and bisphosphonate combination therapy.
